Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598714 | 0.84 | ALDH1A1 (0.47) | MALT1IDO1MEN1KMT2ALMNA | |
| SCHEMBL21598720 | 0.83 | MALT1 (0.44) | MALT1IDO1MEN1KMT2AALDH1A1 | |
| SCHEMBL21598728 | 0.82 | MALT1 (0.49) | MALT1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL25898011 | 0.72 | IDO1 (0.42) | IDO1MEN1KMT2AGAALMNA | |
| SCHEMBL30309355 | 0.72 | IDO1 (0.42) | IDO1MEN1KMT2AGAALMNA | |
| SCHEMBL21598704 | 0.72 | MALT1 (0.33) | MALT1CA1CA2CA9 | |
| SCHEMBL21608246 | 0.72 | RORC (0.44) | IDO1MEN1KMT2AGAALMNA | |
| SCHEMBL12459282 | 0.65 | LMNA (0.56) | MEN1KMT2AGAALMNAALDH1A1 | |
| SCHEMBL2317327 | 0.65 | ALDH1A1 (0.69) | IDO1MEN1KMT2AGAALMNA | |
| SCHEMBL30675553 | 0.65 | PIK3CG (0.49) | IDO1LMNAALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810609-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| US-10888550-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-12 | — | — | US | disclosed |
| WO-2019243965-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243965-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10888550-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | MALT1 1/4885IDO1 2642/4885MEN1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.